Silexion Therapeutics Corp — Form 8-K
Filed September 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 22/100
What the filing says
On September 28, 2026, Silexion Therapeutics Corp offered existing warrant holders a chance to exercise warrants at a reduced exercise price of $0.2603 per share (down from prior levels) and receive new Series F and Series G warrants equal to 100% of shares exercised. The company also issued placement agent warrants at $0.3254 exercise price. Specific dollar amounts and share counts are not disclosed in signature pages; counterparties are unnamed warrant holders and H.C. Wainwright Co., LLC (placement agent). The deal requires shareholder approval for authorized share increase and a reverse split at 1-for-15 to 1-for-25 ratio.
Why this rating
Routine warrant restructuring at micro-cap ($4.2M assets). No new cash raised disclosed; mechanism to reduce dilution pressure while managing share authorization. Low materiality relative to company size.
See more from September 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.